DryEyeCircle
Eye-care professional examining a patient

IPL for dry eye

Intense pulsed light treatment used by some clinics for dry eye associated with meibomian gland dysfunction and eyelid inflammation.

What is IPL?

Intense pulsed light (IPL) delivers controlled pulses of broad-spectrum light to skin around the eyes. In dry eye care, it is commonly considered when meibomian gland dysfunction, rosacea, or eyelid inflammation contributes to unstable tears.

How it works

A clinician shields the eyes and applies light pulses to selected skin areas, often followed by meibomian gland expression. Treatment plans commonly involve a series of visits rather than one session.

Potential benefits

  • Reduce signs and symptoms associated with meibomian gland dysfunction
  • Improve meibomian gland function and tear-film stability for some patients
  • Address facial or eyelid rosacea that may contribute to inflammation

Risks and limitations

  • Temporary redness, swelling, discomfort, pigment changes, or burns can occur
  • It may not be appropriate for some skin types, medications, or light-sensitive conditions
  • Results vary and maintenance sessions may be recommended

Questions to ask a clinic

What IPL device and eye-protection protocol do you use?

Do you combine IPL with gland expression?

What findings from my eye examination support this treatment?

What alternatives should I consider first?

How will we measure whether it is helping?

What will the total treatment and follow-up cost be?

Find local care

Find clinics offering IPL near you

Search clinic listings by country, city, and treatment.

Find clinics

Related treatments

References

  1. Intense pulsed light for the treatment of dry eye disease: a systematic review and meta-analysis Eye & Contact Lens
  2. TFOS DEWS II Management and Therapy Report The Ocular Surface

Last reviewed June 11, 2026. This page is educational and does not provide medical advice. Discuss diagnosis, suitability, risks, and alternatives with a qualified eye-care professional.